Apellis pharmaceuticals, inc. (APLS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16
Operating expenses:
Research and development

249,770

220,968

173,303

151,523

128,362

105,285

87,612

67,591

50,475

40,303

33,405

0

0

0

General and administrative

88,379

67,046

45,968

33,605

26,774

22,639

21,108

16,914

12,676

10,463

6,603

0

0

0

Operating loss

-338,150

-288,015

-219,271

-185,128

-155,137

-127,924

-108,720

-84,505

-63,152

-50,767

-40,008

0

0

0

Loss on extinguishment of debt

-

-1,501

0

0

0

-

-

-

-

-

-

-

-

-

Loss from remeasurement of development derivative liability

-82,509

-14,839

0

0

0

-

-

-

-

-

-

-

-

-

Interest income

6,516

5,108

4,544

4,061

3,427

2,960

0

0

0

-

-

-

-

-

Interest expense

8,610

5,284

2,018

1,994

2,438

2,512

0

0

0

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

0

0

0

-

Other income/(expense), net

91

-175

-24

14

-246

-25

-236

-215

-182

-142

31

0

0

0

Net loss

-422,954

-304,706

-228,374

-194,095

-156,339

-127,502

-108,872

-84,899

-63,691

-51,006

-39,960

0

0

0

Other comprehensive gain:
Unrealized gain on marketable securities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency gain/ (loss)

-262

-30

-168

0

0

-

0

-

-

-

-

-

-

-

Total other comprehensive gain/ (loss)

1,131

-30

-168

0

0

-

0

-

-

-

-

-

-

-

Comprehensive loss, net of tax

-421,823

-304,737

-228,493

-194,217

-156,460

-127,625

-102,276

0

0

-

0

-

-

-

Net loss per common share, basic and diluted

-2.29

-1.81

-1.10

-1.12

-0.87

-0.66

-0.64

-0.61

-0.43

0.20

-1.37

-1.44

-1.07

-0.86

Weighted-average number of common shares used in net loss per common share, basic and diluted

73

121,839

63,752

63,263

57

56,338

56,201

54,691

50,353

30,184

8,442

8,428

8,428

8,428